Table 2.

Hematological and non-hematological adverse events

	AP group (n = 149)				EP group (n = 150)
	Total		≥Grade 3		Total		≥Grade 3
Events (CTCAE v3.0)	n	%	n	%	n	%	n	%
Patients with one or more adverse events	149	100	-	-	148	98.7	-	-
Anemia	48	32.2	10	6.7	48	32.0	10	6.7
Hemoglobin decreased	49	32.9	16	10.7	50	33.3	8	5.3
Leukopenia	97	65.1	52	34.9	85	56.7	29	19.3
Neutropenia	99	66.4	81	54.4	85	56.7	66	44.0
Thrombocytopenia	54	36.2		16.1	40	26.7	11	7.3
Constipation	32	21.5		0	25	16.7		0
Diarrhea	25	16.8	3	2.0	13	8.7	1	0.7
Gastrointestinal disorder	22	14.8	3	2.0	26	17.3	1	0 · 7
Nausea	72	48.3	6	4.0	70	46.7	4	2.7
Vomiting	63	42.3	7	4.7	63	42.0	6	4.0
Fatigue	27	18.1	2	1.3	11	7.3		0
Pyrexia	28	18.8	1	0.7	12	8.0		0
Anorexia	60	40.3	2	1.3	50	33.3	5	3.3
Alopecia	31	20.8	1	0.7	20	13.3		0

Data are number (%)

AP amrubicin/cisplatin, EP etoposide/cisplatin